 Marseille, France, June 10, 2021 GLOBE NEWSWIRE -- Innate Pharma SA Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA Innate or the Company announced it will present the latest preclinical data from its next- generation, proprietary, multi-specific NK cell engager platform known as ANKETTM Antibody-based NK cell Engager Therapeutics at the Federation of Clinical Immunology Societies FOCIS meeting. The presentation will take place at 7 pm CEST today. 